HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein
Open Access
- 1 January 2007
- journal article
- Published by Springer Nature in Retrovirology
- Vol. 4 (1) , 17
- https://doi.org/10.1186/1742-4690-4-17
Abstract
The discovery of diketoacid-containing derivatives as inhibitors of HIV-1 Integrase (IN) (IN inhibitors, IINs) has played a major role in validating this enzyme as an important target for antiretroviral therapy. Since the in vivo efficacy depends on access of these drugs to intracellular sites where HIV-1 replicates, we determined whether the IINs are recognized by the multidrug transporter MDR1-P-glycoprotein (P-gp) thereby reducing their intracellular accumulation. To address the effect of IINs on drug transport, nine quinolonyl diketo acid (DKA) derivatives active on the HIV-1 IN strand transfer (ST) step and with EC50 ranging from 1.83 to >50 μm in cell-based assays were tested for their in vitro interaction with P-gp in the CEM-MDR cell system. IINs were investigated for the inhibition and induction of the P-gp function and expression as well as for multidrug resistance (MDR) reversing ability.Keywords
This publication has 35 references indexed in Scilit:
- Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- The Global Status of Resistance to Antiretroviral DrugsClinical Infectious Diseases, 2005
- Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus MacaquesScience, 2004
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsNew England Journal of Medicine, 2003
- Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitorsAIDS, 2000
- P-Glycoprotein, a gatekeeper in the blood–brain barrierAdvanced Drug Delivery Reviews, 1999
- P-glycoproteins: mediators of multidrug resistanceSeminars in Cell Biology, 1993
- The mdrl gene, responsible for multidrug-resistance, codes for P-glycoproteinBiochemical and Biophysical Research Communications, 1986
- Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell LinesScience, 1983